Physician profile
Nancy E Jones
NPI 1184003436
$5,703.35
in general payments reported to CMS, 2019-2025
42 companies · $2,325 in 2025
The $2,325 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $987 · 2024: $2,392 · 2025: $2,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,703.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $820.95 | 2023-2025 | |
| Pfizer INC. | $560.43 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $538.28 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $493.92 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $372.33 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $349.33 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $342.92 | 2023-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.43 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $234.94 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $221.74 | 2023-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.43 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $123.43 | 2025 | Fanapt, Hetlioz |
| Boston Scientific Corporation | $113.71 | 2023-2025 | Watchman Flx, Wavewriter Alpha Prime 16, Spectra Wavewriter |
| Bayer Healthcare Pharmaceuticals INC. | $106.09 | 2023-2025 | |
| Axsome Therapeutics, INC. | $83.04 | 2025 | Auvelity |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $79.30 | 2023-2024 | Keveyis, Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $79.13 | 2024-2025 | Rexulti |
| Mylan Specialty L.P. | $62.16 | 2024 | Yupelri |
| Esperion Therapeutics, INC. | $62.15 | 2024-2025 | Nexletol |
| Corcept Therapeutics | $62.02 | 2024-2025 | Korlym |
| Sumitomo Pharma America, INC. | $54.41 | 2024-2025 | Gemtesa |
| Abiomed | $40.33 | 2025 | |
| Sanofi-Aventis U.S. LLC | $34.70 | 2025 | |
| Biocryst US Sales Co., LLC | $33.34 | 2024 | Orladeyo |
| Merck Sharp & Dohme LLC | $32.45 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Kowa Pharmaceuticals America, INC. | $31.46 | 2025 | Zoryve |
| Mayne Pharma Commercial LLC | $30.11 | 2024 | |
| Seqirus USA INC | $26.27 | 2025 | Flucelvax, Fluad |
| Daiichi Sankyo INC. | $26.21 | 2025 | Injectafer |
| Stryker Corporation | $25.77 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Teva Pharmaceuticals USA, INC. | $25.48 | 2025 | Austedo Xr |
| Kyowa Kirin, INC. | $25.44 | 2023 | Crysvita |
| Soleno Therapeutics, INC. | $25.21 | 2025 | Vykat Xr |
| Horizon Therapeutics Plc | $24.23 | 2023 | Krystexxa |
| Viatris Specialty LLC | $23.05 | 2025 | Yupelri |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.23 | 2024 | |
| Agios Pharmaceuticals, INC. | $18.51 | 2024 | Pyrukynd |
| Medtronic, INC. | $17.74 | 2025 | Intellis Adaptivestim |
| Cashflow Solutions, LLC | $16.50 | 2023 | Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White |
| Lundbeck LLC | $16.13 | 2024 | Rexulti |
| Edwards Lifesciences Corporation | $15.81 | 2025 | Sapien 3 Ultra Resilia |
| Inspire Medical Systems, INC. | $14.24 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.